Search

Your search keyword '"Tholander B"' showing total 218 results

Search Constraints

Start Over You searched for: "Tholander B" Remove constraint "Tholander B" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
218 results on '"Tholander B"'

Search Results

101. Chemoresistance in Ovarian Cancer: The Role of Malignant Ascites

102. Prognostic significance of preoperative serum CEA in primary mucinous ovarian carcinoma: a retrospective cohort study.

103. STUDY OF OXIDATIVE STRESS IN OVARIAN CANCER.

104. Overexpression of Long Noncoding RNA PTENP1 Inhibits Cell Proliferation and Migration via Suppression of miR-19b in Breast Cancer Cells.

106. Ex vivo activity of cytotoxic drugs and targeted agents in small intestinal neuroendocrine tumors.

107. Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers.

108. Expression of EZH2 in endometrial carcinoma and its effects on proliferation and invasion of endometrial carcinoma cells.

109. CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma.

110. Effectiveness of intraperitoneal or intrapleural administration of triamcinolone acetonide for the control of malignant ascites and pleural effusion (Kansai Clinical Oncology Group-G1102 study).

111. An integrated proteomic and glycoproteomic approach uncovers differences in glycosylation occupancy from benign and malignant epithelial ovarian tumors.

112. Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.

113. Genome-wide Copy-number Alterations in Circulating Tumor DNA as a Novel Biomarker for Patients with High-grade Serous Ovarian Cancer.

114. Serum CA125 and HE4 levels as predictors for optimal interval surgery and platinum sensitivity after neoadjuvant platinum-based chemotherapy in patients with advanced epithelial ovarian cancer.

115. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses.

116. Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis.

117. Targeted therapy in ovarian cancer.

119. Tolerance of weekly paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin.

120. Aberrant sialylation in ovarian cancers.

121. Prediction of Cancer Drug Resistance and implications for Personalized Medicine.

122. Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression.

123. Beyond bevacizumab: an outlook to new anti-angiogenics for the treatment of ovarian cancer.

124. Prostate cancer vaccines: the long road to clinical application.

125. Benchmarking of gastric cancer sensitivity to anticancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy.

126. Survival of women with clear cell and papillary serous endometrial cancer after adjuvant radiotherapy.

127. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.

128. Activity ex vivo of cytotoxic drugs in patient samples of peritoneal carcinomatosis with special focus on colorectal cancer.

129. Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)?

130. Current status of bevacizumab in advanced ovarian cancer.

131. Major clinical research advances in gynecologic cancer in 2012.

132. DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8 T-cell responses and increases PSA doubling time.

133. Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer.

134. Novel activity of acriflavine against colorectal cancer tumor cells.

135. Safety and Efficacy of Intravenous Clevidipine for the Perioperative Control of Acute Hypertension.

137. The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma.

138. Current Treatments and New Possible Complementary Therapies for Epithelial Ovarian Cancer.

140. Regression of orthotopic neuroblastoma in mice by targeting the endothelial and tumor cell compartments.

143. Pharmacodynamic, Pharmacokinetic and Clinical Effects of Clevidipine, an Ultrashort-Acting Calcium Antagonist for Rapid Blood Pressure Control.

144. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study.

145. Small, novel proteins from the mistletoe Phoradendron tomentosum exhibit highly selective cytotoxicity to human breast cancer cells.

148. Selective Cytotoxicity Evaluation in Anticancer Drug Screening of Fractionated Plant Extracts.

150. Short-acting calcium antagonist clevidipine protects against reperfusion injury via local nitric oxide-related mechanisms in the jeopardised myocardium.

Catalog

Books, media, physical & digital resources